Education
About Us
Working with TipRanks
Follow Us
SCYNEXIS (SCYX)
NASDAQ:SCYX
SCYX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.73 - $3.07
Previous CloseN/A
Volume100.07K
Average Volume (3M)119.61K
Market Cap
$39.76M
Enterprise Value$2.48M
Total Cash (Recent Filing)-$2.39M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.62
Next Earnings
May 08, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding38,981,064
10 Day Avg. Volume100,459
30 Day Avg. Volume119,613
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.82
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.66
Enterprise Value/Ebitda-0.08
Forecast
1Y Price Target
$4.50Price Target Upside341.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
SCYNEXIS News
PremiumCompany Announcements
SCYNEXIS Reports 2024 Financial Results and Updates
PremiumPre-Earnings
Is SCYX a Buy, Before Earnings?
PremiumCompany Announcements
SCYNEXIS Advances Antifungal Treatments, Strengthens Financial Outlook
---
Bulls Say, Bears Say
Bulls Say
Commercial OpportunityBrexafemme is an approved drug for vulvovaginal candidiasis, presenting a substantial commercial opportunity due to the unmet need.
Financial StabilityScynexis has sufficient capital to reach milestones with $75M in cash, providing a financial runway into mid-2026.
Bears Say
Manufacturing IssuesLowering the 12-month price target to $4.00, from $8.00, due to ongoing uncertainty with GSK on manufacturing issues related to Brexafemme commercialization.
Revenue RiskUncertainty around the timelines for Brexafemme commercial royalties and GSK's potential filing for approval in invasive fungal infections increases the revenue risk adjustment to 50%.
---
Ownership Overview
4.64% Insiders
21.82% Mutual Funds
0.04% Other Institutional Investors
68.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $0.73 and its highest was $3.07 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $39.76M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is May 08, 2025 which is in 11 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Mar 12, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.07.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.19.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 38,981,064 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went down -5.495%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
---
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (341.18% Upside)
$4.50 (341.18% Upside)
Blogger Sentiment
Bullish
SCYX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.61%
12-Months-Change
Fundamentals
Return on Equity
-33.25%
Trailing 12-Months
Asset Growth
-29.41%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
---
SCYX Stock 12 Month Forecast
Average Price Target
$4.50
▲(341.18% Upside)
Technical Analysis
China Pharma Holdings
―
Durect
―
Rockwell Med
―
Kala Pharmaceuticals
―
China SXT Pharmaceuticals
―
Best Analysts Covering SCYX
1 Year
1 Year Success Rate
0/11 ratings generated profit
1 Year Average Return
-37.68%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -37.68% per trade.
---